Saturday 17 October 2026
Export ALZN’s income statement to Excel — free account
Alzamend Neuro, Inc.
ALZN Healthcare Biotechnology
In the quarter to July 2026, EPS grew 46.9% and free cash flow grew 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.32
0.04
+3.13%
Follow ALZN
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
6.58 | 1.99 | 1.31 | 3.01 |
Net Debt/EBITDA |
4.59 | 1.25 | 0.25 | 2.53 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.17 | 0.79 | 0.97 | 0.38 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(383.88) | (1,690.54) | (28,709.00) | (1,512.70) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.35) | (0.46) | (0.84) | (0.25) | |
Cash per Share |
1.32 | 0.71 | 0.21 | 1.70 | |
Shareholders Equity per Share |
1.29 | 0.57 | 0.22 | 1.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.29 | 0.57 | 0.22 | 1.30 | |
Free Cash Flow |
(1.17) | (1.74) | (2.80) | (1.14) | |
Working Capital |
4.00 | 1.84 | 0.42 | 5.52 | |
Net Current Asset Value |
4.00 | 1.84 | 0.42 | 5.52 | |
| Other line items | |||||
Quick Ratio |
6.20 | 1.46 | 0.53 | 2.77 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.35) | (0.46) | (0.84) | (0.25) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.99 | 1.29 | 0.99 | 1.86 | |
Average Assets |
5.05 | 4.11 | 3.34 | 7.43 | |
Average Common Equity |
4.06 | 2.82 | 2.35 | 5.57 |
Columns are period end dates